PARP inhibitors like olaparib have successfully moved to the clinics and are now approved treatments of BRCA‐mutant ovarian, breast, and pancreatic cancers (Robson et al, 2017; Moore et al, 2018; Golan et al, 2019). Here, PARP1 is linked to pancreatic neoplasm.